Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-02-06 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于注销回购股份、减少注册资本并相应修改公司章程的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the cancellation of repurchased shares, reduction of registered capital, and corresponding amendments to the company's articles of association. It details the number of shares canceled, the reduction in capital, and the specific changes to the company's charter. The document also mentions that these changes will be submitted to the shareholders' meeting for approval. This is a formal announcement about share cancellation and capital reduction, which fits the category of Share Issue/Capital Change (SHA). The document is relatively short (1174 characters) and contains substantive information about capital changes, not just a notice of report publication or a regulatory filing. Therefore, the appropriate classification is SHA with high confidence.
2024-02-06 Chinese
关于提议回购暨公司“提质增效重回报”行动方案的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotech Co., Ltd. regarding a proposed share repurchase plan. It details the reasons for the buyback, the proposer, the buyback method, price, amount, funding source, and timeline. The document emphasizes the company's commitment to investor returns and market stability. It does not contain financial statements or detailed financial results but is a formal disclosure of a capital action (share repurchase). This fits the category of Transaction in Own Shares (POS), which covers announcements of share buybacks or sales by the company itself. The document length is about 2047 characters, consistent with an announcement rather than a full report.
2024-01-31 Chinese
2023年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast announcement by Shenzhen Microchip Biotechnology Co., Ltd. It provides estimated net profit figures for the full year 2023 and compares them to the previous year. It explicitly states that the financial data are preliminary and unaudited, and that the final audited data will be disclosed in the formal 2023 annual report. The document length is short (946 characters) and it serves as a performance forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only, not a full annual report (10-K). FY 2023
2024-01-30 Chinese
关于不向下修正 “微芯转债” 转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('微芯转债'). It details the bond issuance, the conditions triggering a potential downward adjustment of the conversion price, and the board's resolution not to adjust the price despite the triggering event. The document is a regulatory announcement about bond terms and board decisions related to convertible bonds, not a financial report, earnings release, or other report type. It does not contain financial statements or detailed financial analysis but is a formal disclosure of a corporate action related to capital structure. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (1849 characters), but it is not merely announcing the publication of a report; it is the actual announcement of a financing-related decision.
2024-01-17 Chinese
关于 “微芯转债” 预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the potential triggering of a convertible bond price adjustment clause. It details the terms of the convertible bond issuance, the conditions under which the conversion price may be adjusted downward, and the procedures the company will follow if the conditions are met. The document is an informative notice about a possible future event related to the company's convertible bonds, not a financial report or detailed financial data. It is a regulatory announcement about capital market instruments and their terms, specifically a convertible bond price adjustment notice. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-01-10 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It provides specific data on the amount of convertible bonds converted into shares during a recent quarter and cumulatively, as well as the remaining unconverted bonds. The document includes regulatory approval references and detailed share capital changes but does not contain comprehensive financial statements or detailed financial performance analysis. It is a formal disclosure of capital structure changes due to convertible bond conversions, which fits the category of Capital/Financing Update (CAP). The document length is short (1729 characters) and it is not merely announcing the publication of a report but providing substantive update information on convertible bond conversions and share capital changes.
2024-01-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.